文献速递肝胆胰外科围术期管理与 ERAS

新辅助化疗后微创远端胰体尾切除术在可切除及交界可切除胰腺癌中的可行性与安全性

Feasibility and safety of minimally invasive distal pancreatosplenectomy in resectable and borderline resectable pancreatic cancer following neoadjuvant chemotherapy.
PubMed 文献 · Surg Endosc · 2026-01-16

单中心回顾性分析2005年至2024年105例新辅助化疗后行远端胰体尾联合脾切除的晚期胰腺导管腺癌患者,比较开放手术(37例)与微创手术(68例)。微创组估计出血量显著更低(166.8 vs. 269.7 mL,p=0.020),术中输血为零,其他围术期结局、R0切除率、淋巴结检出及长期生存两组相当;倾向性评分匹配后生存仍可比。多变量分析显示估计出血量和N2淋巴结状态是复发的独立预测因素,N2是总生存的唯一独立预测因素,手术方式与肿瘤学结局无关。

要点

  • 新辅助化疗后微创远端胰体尾切除术估计出血量显著低于开放手术。
  • 两组R0切除率、淋巴结检出、病理分期及长期生存无显著差异。
  • 手术方式不是肿瘤学结局的独立预测因素,N2淋巴结状态预测总生存。

核心结论

  • 对经选择的晚期胰腺导管腺癌新辅助化疗后患者,微创远端胰体尾切除术是安全且肿瘤学合理的选项。

研究设计与样本

  • 单中心回顾性队列研究,纳入2005年1月至2024年8月105例新辅助化疗后行远端胰体尾联合脾切除的晚期胰腺导管腺癌患者,开放组37例、微创组68例,行倾向性评分匹配前后比较。

主要发现

  • 微创组估计出血量显著低于开放组(166.8 vs. 269.7 mL,p=0.020),微创组无术中输血。
  • 手术时间、术后并发症发生率及住院时间两组相当。
  • R0切除率、淋巴结检出数目及病理分期两组无显著差异。
  • 无病生存和总生存两组相似,包括接受FOLFIRINOX为基础新辅助及辅助化疗的患者;倾向性评分匹配后生存仍可比。
  • 多变量分析显示估计出血量和N2淋巴结状态是复发的独立预测因素,N2是总生存的唯一独立预测因素,手术方式与肿瘤学结局无关。

临床怎么用

  • 对经仔细选择的晚期胰腺导管腺癌新辅助化疗后患者,可考虑微创远端胰体尾切除术。
  • 术前应评估N2淋巴结状态以辅助判断预后。

局限性

  • 单中心回顾性设计,样本量有限,选择偏倚可能存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of minimally invasive surgery (MIS) in advanced pancreatic ductal adenocarcinoma (PDAC) remains controversial, particularly after neoadjuvant chemotherapy. Most previous studies have excluded such patients, and evidence supporting MIS in this context is limited. We evaluated the safety, technical feasibility, and oncologic outcomes of minimally invasive distal pancreatectomy (MIDP) following neoadjuvant chemotherapy in patients with advanced pancreatic cancer. METHODS: We retrospectively reviewed 105 patients who underwent distal pancreatectomy with splenectomy for advanced PDAC following neoadjuvant chemotherapy at a single institution between January 2005 and August 2024. Patients were categorized into open (ODP, n = 37) and minimally invasive (MIDP, n = 68) groups. Perioperative outcomes, pathologic features, and long-term survival were compared before and after propensity score matching. Subgroup and multivariable analyses were performed. RESULTS: MIDP was associated with significantly lower estimated blood loss compared with ODP (166.8 vs. 269.7 mL, p = 0.020), and no patient in the MIDP group required intraoperative transfusion. Other perioperative outcomes, including operation time, postoperative morbidity, and length of hospital stay, were comparable between groups. R0 resection rates, lymph node yield, and pathologic staging did not differ significantly. Long-term disease-free and overall survival were similar between groups, including in patients who received FOLFIRINOX-based neoadjuvant and adjuvant chemotherapy. After propensity score matching, survival outcomes remained comparable. Multivariable analysis identified estimated blood loss and N2 nodal status as independent predictors of recurrence, while N2 nodal status was the only independent predictor of overall survival. The surgical approach was not associated with oncologic outcomes. CONCLUSIONS: Minimally invasive distal pancreatectomy is a safe and oncologically sound option for selected patients with advanced PDAC after neoadjuvant chemotherapy. With careful patient selection, MIS may be effectively applied even in technically challenging cases.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Hong SS, Hwang HK, Kim SH, et al. Feasibility and safety of minimally invasive distal pancreatosplenectomy in resectable and borderline resectable pancreatic cancer following neoadjuvant chemotherapy. Surg Endosc. 2026. PMID: 41545569. doi:10.1007/s00464-025-12533-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。